Moderna's Analyst Upgrades Come With a Catch: The Ratings Haven't Moved

Moderna drew a wave of upward target revisions this week, but the fine print tells a more guarded story. Three banks have now lifted their price objectives on the biotech, yet not one has shifted its actual recommendation — a distinction that matters as investors brace for a pair of catalysts that will test the stock's recent strength.

Bank of America raised its target to $220 from $200, keeping its rating at "Neutral." Goldman Sachs moved from $120 to $137 on Thursday, also holding at "Neutral." And Oddo BHF went furthest, lifting its objective to $251 from $170. The pattern is consistent: analysts are marking their models higher without turning more constructive on the shares themselves.

That gap between a rising target and a static rating is the crux of the current debate. A higher price objective reflects a revised valuation; an unchanged call caps how far that signal should be read. The banks have raised their bar without adopting a more aggressive stance.

Positioning, Not Pronouncements

The stock climbed 4.6% in the prior session as traders staked out positions ahead of pending melanoma data, with the Bank of America target increase lending support. Media reports pointed to pre-data positioning as the primary driver, with the analyst action playing a secondary role. Friday's pullback, by contrast, was framed by Reuters as profit-taking and caution following the sharp rally. Shares were back in positive territory during yesterday's session.

Read together, the two moves describe shifting expectations rather than a verdict on the company's worth. The rally should not be mistaken for a reaction to the higher targets alone — the looming data release sits at the center of the story.

The October 24 Readout

Full Phase 3 results from INTerpath-001 are due at the ESMO congress on October 24. The trial compares intismeran autogene plus Keytruda against Keytruda alone in resected high-risk melanoma, a program Moderna is developing jointly with Merck. Moderna has scheduled an investor call for the same afternoon.

An announced presentation, however, does not preview an outcome. Neither the direction of the study nor its commercial weight can be inferred from the date alone. That is precisely where an optimistic reading of the recent trading runs into its limit: investors positioned ahead of the data, not in response to results already in hand.

Building the Commercial Bridge

Separately, Tempus AI disclosed on October 7 an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene. The operative word is "potential." The partnership is concrete preparation, not confirmation of a future commercial success. It can help pave the road from clinical progress to economic execution, but it substitutes for neither trial results nor proof of commercial viability.

A second checkpoint follows on November 6, when Moderna releases third-quarter 2026 results alongside a business update, a date the company confirmed on October 13.

Two distinct lenses now sit side by side: the clinical outlook for the Merck-partnered program and the company's financial trajectory. Keeping them apart is the discipline the moment demands. The appeal of the Moderna story lies in the possible connection between the two — and the analytical trap is treating that connection as already made.